Medilink Pharma Limited 15586349 false 2024-03-23 2025-03-31 2025-03-31 The principal activity of the company is that of a dispensing chemist. Digita Accounts Production Advanced 6.30.9574.0 true false true 15586349 2024-03-23 2025-03-31 15586349 2025-03-31 15586349 bus:OrdinaryShareClass1 2025-03-31 15586349 bus:OrdinaryShareClass2 2025-03-31 15586349 bus:OrdinaryShareClass3 2025-03-31 15586349 bus:Consolidated 2025-03-31 15586349 core:AcceleratedTaxDepreciationDeferredTax 2025-03-31 15586349 core:ShareCapital 2025-03-31 15586349 core:CurrentFinancialInstruments 2025-03-31 15586349 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 15586349 core:Non-currentFinancialInstruments 2025-03-31 15586349 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 15586349 core:Goodwill 2025-03-31 15586349 core:AdditionsToInvestments 2025-03-31 15586349 core:FurnitureFittingsToolsEquipment 2025-03-31 15586349 core:MotorVehicles 2025-03-31 15586349 bus:SmallEntities 2024-03-23 2025-03-31 15586349 bus:Audited 2024-03-23 2025-03-31 15586349 bus:FilletedAccounts 2024-03-23 2025-03-31 15586349 bus:SmallCompaniesRegimeForAccounts 2024-03-23 2025-03-31 15586349 bus:RegisteredOffice 2024-03-23 2025-03-31 15586349 bus:Director1 2024-03-23 2025-03-31 15586349 bus:Director2 2024-03-23 2025-03-31 15586349 bus:OrdinaryShareClass1 2024-03-23 2025-03-31 15586349 bus:OrdinaryShareClass2 2024-03-23 2025-03-31 15586349 bus:OrdinaryShareClass3 2024-03-23 2025-03-31 15586349 bus:PrivateLimitedCompanyLtd 2024-03-23 2025-03-31 15586349 bus:Agent1 2024-03-23 2025-03-31 15586349 core:Goodwill 2024-03-23 2025-03-31 15586349 core:ComputerEquipment 2024-03-23 2025-03-31 15586349 core:FurnitureFittings 2024-03-23 2025-03-31 15586349 core:FurnitureFittingsToolsEquipment 2024-03-23 2025-03-31 15586349 core:MotorVehicles 2024-03-23 2025-03-31 15586349 core:Vehicles 2024-03-23 2025-03-31 15586349 core:AllSubsidiaries 2024-03-23 2025-03-31 15586349 core:KeyManagementPersonnel 2024-03-23 2025-03-31 15586349 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-03-23 2025-03-31 15586349 core:ParentEntities 2024-03-23 2025-03-31 15586349 core:Subsidiary1 2024-03-23 2025-03-31 15586349 core:Subsidiary1 1 2024-03-23 2025-03-31 15586349 core:Subsidiary2 2024-03-23 2025-03-31 15586349 core:Subsidiary2 1 2024-03-23 2025-03-31 15586349 countries:EnglandWales 2024-03-23 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 15586349

Prepared for the registrar

Medilink Pharma Limited

Annual Report and Financial Statements

for the Period from 23 March 2024 to 31 March 2025

 

Medilink Pharma Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 12

 

Medilink Pharma Limited

Company Information

Directors

Mr N Nasrullah

Mr D S Patel

Registered office

Windsor House
Bayshill Road
Cheltenham
GL50 3AT

Auditors

Hazlewoods LLP Windsor House
Bayshill Road
Cheltenham
GL50 3AT

 

Medilink Pharma Limited

(Registration number: 15586349)
Balance Sheet as at 31 March 2025

Note

2025
£

Fixed assets

 

Intangible assets

4

1,115,051

Tangible assets

5

14,017

Investments

6

87,109

 

1,216,177

Current assets

 

Stocks

45,328

Debtors

7

180,033

Cash at bank and in hand

 

183,668

 

409,029

Creditors: Amounts falling due within one year

8

(891,947)

Net current liabilities

 

(482,918)

Total assets less current liabilities

 

733,259

Creditors: Amounts falling due after more than one year

8

(666,900)

Deferred tax liabilities

9

(3,505)

Net assets

 

62,854

Capital and reserves

 

Called up share capital

11

100

Retained earnings

62,754

Shareholders' funds

 

62,854

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 22 December 2025 and signed on its behalf by:
 


Mr N Nasrullah
Director


Mr D S Patel
Director

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Windsor House
Bayshill Road
Cheltenham
GL50 3AT
England

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
 

Judgements

No significant judgements have been made by management in preparing these financial statements.

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company.

The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.

Government grants

Government grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures and fittings

15% reducing balance basis

Computer equipment

25% reducing balance basis

Motor vehicles

25% reducing balance basis

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date.

Negative goodwill arising on an acquisition is recognised on the face of the balance sheet on the acquisition date and subsequently the excess up to the fair value of non-monetary assets acquired is recognised in profit or loss in the periods in which the non-monetary assets are recovered.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

10 years straight line

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.


Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025


Impairment
Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable value of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

The recoverable amount of goodwill is derived from measurement of the present value of the future cash flows of the cash-generating units ('CGUs') of which the goodwill is a part. Any impairment loss in respect of a CGU is allocated first to the goodwill attached to that CGU, and then to other assets within that CGU on a pro-rata basis.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the assets (other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 7.

 

4

Intangible assets

Goodwill
 £

Cost

Transfer on hive up

1,143,642

At 31 March 2025

1,143,642

Amortisation

Amortisation charge

28,591

At 31 March 2025

28,591

Carrying amount

At 31 March 2025

1,115,051

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

 

5

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost

Additions and at 31 March 2025

12,401

3,152

15,553

Depreciation

Charge for the period and at 31 March 2025

1,076

460

1,536

Carrying amount

At 31 March 2025

11,325

2,692

14,017

 

6

Investments

2025
£

Investments in subsidiaries

87,109

Subsidiaries

£

Cost

Additions and at 31 March 2025

87,109

Carrying amount

At 31 March 2025

87,109

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

Details of undertakings

Details of the investments in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

2025

Subsidiary undertakings

PM Hawkes Limited

*

Ordinary shares

100%

SJ & JW Evans Limited

*

Ordinary shares

100%

*The registered office of the subsidiary is 231 Worcester Road, Malvern, Worcestershire, WR14 1SU

The principal activity of the subsidiaries is that of a dormant company.

 

7

Debtors

2025
£

Trade debtors

107,718

Prepayments

544

Other debtors

71,771

180,033

 

8

Creditors

Note

2025
£

Due within one year

 

Loans and borrowings

10

28,153

Trade creditors

 

145,787

Amounts due to related parties

 

639,111

Taxation and social security

 

30,178

Accruals and deferred income

 

14,582

Other creditors

 

34,136

 

891,947

Note

2025
£

Due after one year

 

Loans and borrowings

10

666,900

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

 

9

Deferred tax

Deferred tax assets and liabilities

2025

Liability
£

Capital allowances in excess of depreciation

3,505

 

10

Loans and borrowings

Current loans and borrowings

2025
£

Bank borrowings

28,153

Non-current loans and borrowings

2025
£

Bank borrowings

666,900

Bank borrowings
The bank loan with carrying value at the year end of £695,053 is denominated in Sterling with an interest rate of 2.15% above base rate per annum. The loan is repayable in monthly instalments over the next 4 years and 7 months.

The bank loan is secured via a cross guarantee between PM Hawkes Limited and Raylane Limited, a personal guarantee from the directors and a charge over the leasehold premises from which the pharmacy operates.

 

Medilink Pharma Limited

Notes to the Financial Statements for the Period from 23 March 2024 to 31 March 2025

 

11

Share capital

Allotted, called up and fully paid shares

 

31 March 2025

 

No.

£

Ordinary of £1 each

98

98

Ordinary A of £1 each

1

1

Ordinary B of £1 each

1

1

 

100

100

The different classes of shares referred to above carry separate rights to dividends, but in all other significant respects, rank pari passu.

New shares allotted

During the period 98 Ordinary having an aggregate nominal value of £98 were allotted for an aggregate consideration of £98.

During the period 1 Ordinary A having an aggregate nominal value of £1 were allotted for an aggregate consideration of £1.

During the period 1 Ordinary B having an aggregate nominal value of £1 were allotted for an aggregate consideration of £1.

 

12

Related party transactions

Key management personnel

Key management personnel are considered to be the directors of the company.

Summary of transactions with key management

As at the year end the company was owed £732 by the directors. This amount is included within other debtors. There are no fixed repayment terms and no interest is charged.
 

Summary of transactions with parent

As at the year end the company owed £250,000 to N N Pharma Ltd. This amount is included within amounts due to related parties. There are no fixed repayment terms and no interest is charged.

As at year end the company owed £257,144 to Raylane Limited. This amount is included within amounts due to related parties. There are no fixed repayment terms and no interest is charged.

Summary of transactions with subsidiaries

As at the year end the company owed £131,843 to PM Hawkes Ltd. This amount is included within amounts owed to related parties. There are no fixed repayment terms and no interest is charged.

As at the year the company owed £124 to SJ & JW Evans Ltd. This amount is included within amounts owed to related parties. There are no fixed repayment terms and no interest is charged.

 

13

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 22 December 2025 was Joanne Hartness, who signed for and on behalf of Hazlewoods LLP.